TY - JOUR
T1 - Longitudinal Tau PET Using 18F-Flortaucipir
T2 - the Effect of relative Cerebral Blood Flow on (semi)quantitative parameters
AU - Visser, Denise
AU - Tuncel, Hayel
AU - Ossenkoppele, Rik
AU - Yaqub, Maqsood
AU - Wolters, Emma E.
AU - Timmers, Tessa
AU - Weltings, Emma
AU - Coomans, Emma M.
AU - den Hollander, Marijke E.
AU - van der Flier, Wiesje M.
AU - van Berckel, Bart N. M.
AU - Golla, Sandeep S. V.
N1 - Publisher Copyright: © 2023 by the Society of Nuclear Medicine and Molecular Imaging. Funding Information: Van der Flier received grant support from ZonMW, NWO, EU-FP7, Alzheimer Nederland, Funding Information: This study was funded by a ZonMW Memorabel grant. Publisher Copyright: © 2023 Society of Nuclear Medicine Inc.. All rights reserved.
PY - 2023/2/1
Y1 - 2023/2/1
N2 - Semi-quantitative PET measures like SUVr) have several advantages over quantitative measures, such as practical applicability and relative computational simplicity. However, SUVr may potentially be affected by changes in blood flow, whereas quantitative measures such as BP ND are not. For 18F-flortaucipir-PET the sensitivity of SUVr for changes in blood flow is currently unknown. Therefore we compared semi-quantitative (SUVr) and quantitative (BP ND) parameters of longitudinal 18F-flortaucipir PET scans, and assessed their vulnerability to changes in blood flow. Subjects with subjective cognitive decline (SCD; n=38) and Alzheimer's disease (AD) patients (n=24) underwent baseline (BL) and 2-year follow-up (FU) dynamic 18F-flortaucipir-PET scans. BP ND and R 1 were estimated using receptor parametric mapping (RPM) and SUVr (80-100min) was calculated. Regional SUVrs were compared to corresponding DVR (= BP ND+1) using paired T-tests. Additionally, simulations were performed to model effects of (large(r)) flow changes in different binding categories. Results in SCD and AD showed only minor differences between SUVr and BP ND changes over time. R 1 changes were small in all groups. Simulations illustrated a variable bias for SUVr depending on the amount of binding. Concluding, SUVr provided an accurate estimate of changes in specific binding for 18F-flortaucipir over a two-year follow-up during which changes in flow were small. Notwithstanding, simulations showed that large(r) flow changes may affect 18F-flortaucipir SUVr. Given that it is currently unknown to what order of magnitude pharmacotherapeutic interventions may induce changes in cerebral blood flow, caution may be warranted in situations where changes in flow are potentially large(r) like in clinical trials.
AB - Semi-quantitative PET measures like SUVr) have several advantages over quantitative measures, such as practical applicability and relative computational simplicity. However, SUVr may potentially be affected by changes in blood flow, whereas quantitative measures such as BP ND are not. For 18F-flortaucipir-PET the sensitivity of SUVr for changes in blood flow is currently unknown. Therefore we compared semi-quantitative (SUVr) and quantitative (BP ND) parameters of longitudinal 18F-flortaucipir PET scans, and assessed their vulnerability to changes in blood flow. Subjects with subjective cognitive decline (SCD; n=38) and Alzheimer's disease (AD) patients (n=24) underwent baseline (BL) and 2-year follow-up (FU) dynamic 18F-flortaucipir-PET scans. BP ND and R 1 were estimated using receptor parametric mapping (RPM) and SUVr (80-100min) was calculated. Regional SUVrs were compared to corresponding DVR (= BP ND+1) using paired T-tests. Additionally, simulations were performed to model effects of (large(r)) flow changes in different binding categories. Results in SCD and AD showed only minor differences between SUVr and BP ND changes over time. R 1 changes were small in all groups. Simulations illustrated a variable bias for SUVr depending on the amount of binding. Concluding, SUVr provided an accurate estimate of changes in specific binding for 18F-flortaucipir over a two-year follow-up during which changes in flow were small. Notwithstanding, simulations showed that large(r) flow changes may affect 18F-flortaucipir SUVr. Given that it is currently unknown to what order of magnitude pharmacotherapeutic interventions may induce changes in cerebral blood flow, caution may be warranted in situations where changes in flow are potentially large(r) like in clinical trials.
KW - Alzheimer disease
KW - Alzheimer's disease
KW - dynamic (DVR/BP )
KW - dynamic (DVR/BPND)
KW - longitudinal 18F-flortaucipir PET
KW - longitudinal F-flortaucipir-PET
KW - quantification
KW - static (SUVr)
UR - http://www.scopus.com/inward/record.url?scp=85147317671&partnerID=8YFLogxK
U2 - https://doi.org/10.2967/jnumed.122.263926
DO - https://doi.org/10.2967/jnumed.122.263926
M3 - Article
C2 - 36265910
SN - 1535-5667
VL - 64
SP - 281
EP - 286
JO - Journal of nuclear medicine : official publication, Society of Nuclear Medicine
JF - Journal of nuclear medicine : official publication, Society of Nuclear Medicine
IS - 2
ER -